NeuroOne Medical Technologies Corp (NMTC)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
$1.66-1.78%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
Broken: Primary pillar broken — Achieve at least $10.5M revenue in fiscal 2026: FY26 revenue guidance mid $9.85M vs $10.5M target.
NeuroOne aims for $10.5M revenue in 2026. Sales grew to $1.86M in Q2. The company beat earnings in recent quarters. New products could drive future growth.
Revenue missed the $2.4M Q2 target. The company is still losing money. Legal and audit issues raise risks. The stock fell 40% from its high.
The price is about 40% below our fair value near $5. Analysts expect 45% revenue growth. We see risk in meeting these goals.
Breaks if: New material legal or audit issues reported
Breaks if: EPS loss worsens beyond -$0.51 in FY27
Breaks if: Q2 revenue falls below $2.4M
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story in the healthcare sector. The company is currently loss-making, and its recent financial performance has been weak, but there are signs of progress in product revenue and commercialization efforts.
The market appears to have priced in a low level of expectations, as NMTC is seen as cheap compared to its peers. However, there is a significant expectations gap, indicating that investors are cautious about the company's ability to meet its targets.
Management is on track to achieve its revenue goals, but the company remains at risk of missing estimates due to its history of earnings misses. The near-term outlook is uncertain, especially with high risk factors and recent weak performance.
The long-term thesis hinges on the company's ability to meet its revenue targets and successfully expand its product offerings. Additionally, broader sector performance and economic conditions, such as job growth, will play a critical role in shaping NMTC's trajectory.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company expects $11.2 million in product orders. This supports the goal of $10.5 million in revenue for fiscal 2026. However, earnings missed by $0.10 and revenue fell short of estimates. This indicates potential challenges in achieving revenue targets.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Revenue falls below $10.5M in fiscal 2026
The company aims to achieve at least $10.5 million in product revenue for fiscal year 2026.
In the next 1 to 3 years, NMTC's performance will depend on its execution of key priorities and external market conditions. Not investment advice.